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Hepatitis Awareness Month and
National Hepatitis Testing Day —
May 2014
In the United States, May is Hepatitis Awareness
Month, and May 19 is National Hepatitis Testing Day.
Although care and treatment can be life-saving, many
of the estimated 800,000 to 1.4 million persons living
with hepatitis B virus (HBV) infection and the estimated
3 million persons living with hepatitis C virus (HCV)
infection are unaware of their infection and are not
receiving necessary care and treatment (1). Guided by
the goals of the 2014 U.S. Department of Health and
Human Services Action Plan for the Prevention, Care,
and Treatment of Viral Hepatitis (1), CDC is working
to expand access to HBV and HCV testing, care,
and treatment. This issue of MMWR reports on the
progress of these CDC activities in reaching the national
prevention goals.
The first report examines projects (based on the Project
ECHO model of videoconference and case-based learning)
to strengthen HCV primary care capacity in Arizona and
Utah. In the second report, programs in three sites (New
York City, Minneapolis-St. Paul, and San Diego) targeted
HBV testing for persons born in countries where HBV
infection is endemic (≥2% prevalence). Both programs
were successful in reaching persons in underserved populations (in predominantly rural settings for hepatitis C and
among foreign-born persons for hepatitis B) and linking
them to appropriate care and treatment. Broader expansion
of programs like these will help prevent HBV and HCV
transmission and disease.
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Hepatitis C virus (HCV) infection is the leading reason for
liver transplantation and a common cause of hepatocellular
carcinoma, the most rapidly increasing cause of cancer-related
deaths in the United States (1,2). Of the approximately 3 million persons living with HCV infection in the United States,
an estimated 38% are linked to care, 11% are treated, and 6%
achieve cure (3). Recent development of highly effective and
well-tolerated medications, such as sofosbuvir and simeprevir,
to treat chronic HCV infection shows promise in curbing rising HCV-related morbidity and mortality, with the potential
to cure >90% of patients. To fully benefit from these new
treatments, improvement in linkage to care and treatment is
urgently needed.* Lack of provider expertise in HCV treatment
* Information available at http://www.hcvguidelines.org.
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and limited access to specialists are well-documented barriers
to HCV treatment (4,5). In September 2012, CDC funded
programs in Utah and Arizona to improve access to primary
care providers with the capacity to manage and treat HCV
infection. Both programs were modeled on the Extension for
Community Healthcare Outcomes (Project ECHO), developed
by the University of New Mexico’s Health Sciences Center in
2003 to build primary care capacity to treat diseases among
rural, underserved populations through videoconferencing and
case-based learning in “teleECHO” clinics. To assess the effectiveness of these programs in improving primary care provider
capacity and increasing the number of patients initiating treatment, process and patient outcome data for each state program
were analyzed. In both states, Project ECHO was successfully
implemented, training 66 primary care clinicians, predominantly from rural settings. Nearly all (93%) of the clinicians had
no prior experience in care and treatment of HCV infection.
In both states combined, 129 (46%) of HCV-infected patients
seen in teleECHO clinics received antiviral treatment, more
than doubling the proportion of patients expected to receive
treatment (3). These findings demonstrate Project ECHO’s
ability to expand primary care capacity to treat HCV infection,
notably among underserved populations.
Project ECHO was designed to build primary care clinicians’ capacity to treat chronic, common, and complex diseases through weekly teleECHO clinics called “Knowledge
Networks,” in which primary care clinicians present their cases,
through videoconferencing, to specialists who provide advice

and clinical mentoring. Working together and supplemented
with short didactic presentations (e.g., on HCV diagnosis and
management) by interdisciplinary experts, the communitybased providers and specialists manage patients following
evidence-based protocols.
From September 30, 2012, to February 28, 2014, ECHO
programs in Utah and Arizona recruited providers serving
populations at increased risk for HCV infection (e.g., persons
born during 1945–1965) and in areas with a shortage of HCV
specialists. Providers with an interest in treating HCV infection
and access to videoconferencing technology (e.g., access to a
webcam and software provided by Project ECHO) were eligible
to participate. Utah targeted community-based providers in
seven neighboring states (Oregon, California, Idaho, Utah,
Montana, Wyoming, and Colorado) with an estimated population of 10 million, 60% of whom resided in rural settings.
Arizona recruited community-based providers within nine of
Arizona’s 15 counties, representing approximately 90% of the
state’s population of nearly 7 million.
Utah recruited providers throughout the project period
via outreach at professional societies, departments of health,
community-based organizations, and university-based referral
clinics. Arizona recruited all providers within the first 3 months
of the project through outreach at community health centers.
In both states, Project ECHO staff initially visited providers
to train them in HCV diagnosis and management and in
the protocol for patient presentation. Providers then began
weekly participation in teleECHO clinic sessions, following
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the Project ECHO format, and lasting about 1 to 1.5 hours.
Providers were eligible to receive continuing medical education
credits. Utah’s team of specialists consisted of a hepatologist,
psychiatrist, and pharmacist; Arizona’s team consisted of a
hepatologist and nurse practitioner. In Utah, teleECHO clinics
were held once weekly.
After the initial case presentation, providers were encouraged
to attend sessions at specific time intervals (4, 8, 12, 24, and
48 weeks, and 6 months post-treatment) based on standards
for monitoring treatment; three to 14 primary care clinicians
attended each session (median = six). In Arizona, teleECHO
clinics were held once weekly and were site-specific; one to 21
primary care clinicians attended each session (median = seven).
Providers at each site were asked to present every patient,
those newly diagnosed and those on treatment, at the weekly
teleECHO clinic sessions. A monthly synchronous cohort
treatment initiation approach was followed, where patients
at each site were started on treatment in like timeframes and
managed together as a cohort to simplify monitoring. At larger
provider sites, an HCV coordinator supported providers in
patient management (i.e., medication adherence and insurance
enrollment). In Utah, the program collaborated with the local
health department to identify HCV-infected patients requiring
linkage to care and those who were lost to follow-up. Data from
each state Project ECHO program (e.g., types of providers,

practice settings, patient characteristics, and clinical outcomes)
are summarized in this report.
Over the 17-month period (September 30, 2012–
February 28, 2014), a total of 90 unique attendees participated
in teleECHO clinics in the two states; of these, 66 (73%) were
primary care clinicians with practices in predominantly rural
settings and at community health centers (Table 1). A total of
280 unique cases of chronic HCV infection were presented in
teleECHO sessions (Table 2). In both states, cases were predominantly among persons who were U.S.-born, non-Hispanic
white, and born during 1945–1965. A history of injecting drug
use was known for 41.4% (116 of 280) of patients. A total
136 of patients seen were known to have health-care coverage;
Medicaid was the most common type of coverage (61.8%)
followed by private insurance (23.5%). HCV genotype 1
infection was the most common type of infection (62.9%).
Of patients with an available aspartate aminotransferase (AST)
to platelet ratio index (APRI)† score, 41% (100 of 243) had
a score ≥1, indicating the presence of advanced fibrosis or
cirrhosis. Among 129 (46.1% of 280) patients who started
treatment, 70.5% (91 of 129) were treated with an interferonbased regimen, and 26.4% (34 of 129) were treated with a
† APRI calculated as (AST [IU/L] / upper limit of normal AST [IU/L]) / platelets
[109/L] x 100.

TABLE 1. Number and percentage of clinicians participating in Project ECHO case-based learning clinics (teleECHO clinics), by selected
characteristics — Arizona and Utah, September 30, 2012–February 28, 2014
Total
Characteristic
Total no. of sessions
Total no. of attendees
No. of unique attendees
Occupation of attendees
Physician (MD or DO degree)
Other clinician (RN, PA, or NP degree)
Pharmacist
Medical assistant
Students (medical, pharmacy, or nursing)
Other
No. of unique primary care clinician attendees*
Practice setting of primary care clinicians*†
Urban
Rural
Practice type of primary care clinicians*†
Community health center (federally qualified health centers)
Private practice
Hospital-affiliated practice
Academic medical center
Indian Health Service
Church-sponsored indigent care clinic
Primary care clinician without prior experience in treating HCV*†

No.

Utah
(%)

179
1,722
90

No.

Arizona
(%)

47
304
39

No.

(%)

132
1,418
51

44
24
4
12
4
2
66

(48.9)
(26.7)
(4.4)
(13.3)
(4.4)
(2.2)
(73.3)

23
12
2
0
1
1
35

(59.0)
(30.8)
(5.1)
—
(2.6)
(2.6)
(89.7)

21
12
2
12
3
1
31

(41.2)
(23.5)
(3.9)
(23.5)
(5.9)
(2.0)
(60.8)

15
51

(22.7)
(77.3)

14
21

(40.0)
(60.0)

1
30

(3.2)
(96.8)

32
8
16
4
4
2
62

(48.5)
(12.1)
(24.2)
(6.1)
(6.1)
(3.0)
(93.3)

12
8
8
4
3
0
32

(34.3)
(22.9)
(22.9)
(11.4)
(8.6)
—
(91.4)

20
0
8
0
1
2
30

(64.5)
—
(25.8)
—
(3.2)
(6.5)
(96.8)

Abbreviations: ECHO = Extension for Community Healthcare Outcomes; HCV = hepatitis C virus.
* With an MD, DO, NP, or PA degree.
† Denominator is the number of unique primary care clinicians.
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TABLE 2. Number and percentage of HCV-infected patients seen in Project ECHO case-based learning clinics (teleECHO clinics), by selected
characteristics — Arizona and Utah, September 30, 2012–February 28, 2014
Total
No.

Characteristic
Total no. of patients
Birth country
U.S.-born
Foreign-born (Mexico)
Unknown/missing
Median age (range) (yrs)
Birth year
Before 1945
1945–1965
After 1965
Race/Ethnicity
Non-Hispanic black
Non-Hispanic white
Hispanic
American Indian/Alaska Native
Unknown/missing
Health insurance
Yes
No
Unknown/missing
Type of health-care coverage*
Medicare
Medicaid
Private
Other public
None
Unknown/missing
HCV risk factor
Known injection drug use ever
Known injection drug use within 12 mos
Unknown injection drug use
Known HIV infection
AST to platelet ratio index†
<1
>1
Unknown/missing
Genotype
1
2
3
4
Unknown/missing
Started on treatment for HCV infection
Treatment regimen§
Pegylated interferon + ribavirin
Pegylated interferon + ribavirin + telaprevir
Pegylated interferon + ribavirin + boceprevir
Sofosbuvir + simeprevir
Sofosbuvir + Pegylated interferon + ribavirin
Sofosbuvir + ribavirin
Unknown/missing

280
203
5
72
55 (17–75)

Arizona
(%)
(100.0)
(72.5)
(1.8)
(25.7)

No.
159
84
3
72
55 (17–74)

Utah
(%)
(100.0)
(52.8)
(1.9)
(45.3)

No.
121
119
2
0
52.75 (23–75)

(%)
(100.0)
(98.3)
(1.7)
—

10
200
70

(3.6)
(71.4)
(25.0)

8
111
40

(5.0)
(69.8)
(25.2)

2
89
30

(1.7)
(73.6)
(24.8)

6
177
27
15
55

(2.1)
(63.2)
(9.6)
(5.4)
(19.6)

2
75
19
11
52

(1.3)
(47.2)
(11.9)
(6.9)
(32.7)

4
102
8
4
3

(3.3)
(84.3)
(6.6)
(3.3)
(2.5)

136
35
109

(48.6)
(12.5)
(38.9)

76
14
69

(47.8)
(8.8)
(43.4)

60
21
40

(49.6)
(17.4)
(33.1)

18
84
32
2
35
109

(13.2)
(61.8)
(23.5)
(1.5)
(25.7)
(80.1)

15
46
15
0
14
69

(19.7)
(60.5)
(19.7)
—
(18.4)
(90.8)

3
38
17
2
21
40

(5.0)
(63.3)
(28.3)
(3.3)
(35.0)
(66.7)

116
1
164
3

(41.4)
(0.4)
(58.6)
(1.1)

50
0
109
1

(31.4)
—
(68.6)
(0.6)

66
1
55
2

(54.5)
(0.8)
(45.5)
(1.7)

143
100
37

(51.1)
(35.7)
(13.2)

96
47
16

(60.4)
(29.6)
(10.1)

47
53
21

(38.8)
(43.8)
(17.4)

176
39
36
3
26
129

(62.9)
(13.9)
(12.9)
(1.1)
(9.3)
(46.1)

94
20
20
2
23
81

(59.1)
(12.6)
(12.6)
(1.3)
(14.5)
(50.9)

82
19
16
1
3
48

(67.8)
(15.7)
(13.2)
(0.8)
(2.5)
(39.7)

30
54
7
6
18
10
4

(23.3)
(41.9)
(5.4)
(4.7)
(14.0)
(7.8)
(3.1)

12
39
1
6
13
10
0

(14.8)
(48.1)
(1.2)
(7.4)
(16.0)
(12.3)
—

18
15
6
0
5
0
4

(37.5)
(31.3)
(12.5)
—
(10.4)
—
(8.3)

Abbreviations: ECHO = Extension for Community Healthcare Outcomes; HCV = hepatitis C virus; HIV = human immunodeficiency virus; AST = aspartate aminotransferase.
* Denominator is the number of patients with health-care coverage.
† Calculated as (AST [IU/L] / upper limit of normal AST [IU/L]) / platelets [109/L] x 100.
§ Denominator is number of patients who started treatment.
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regimen containing sofosbuvir, a drug approved in December
2013. Arizona and Utah started treatment with a sofosbuvirbased regimen in 35.8% (29 of 81) and 10.4% (five of 48) of
patients, respectively, during December 2013–February 2014.
Discussion

The implementation of the Project ECHO model in two
states demonstrated the utility of this care model in expanding
the capacity of primary care clinicians to treat HCV infection.
By building collaborations with specialists facilitated by regular
videoconferencing, both states recruited and trained clinicians
from predominantly rural settings. Almost all (93.9%) of the
primary care clinicians had no prior experience in managing
HCV infection. Approximately 46% of all patients seen started
treatment, a proportion that was more than twice that observed
from a CDC study in which 14%–22% of those detected
started treatment (3). In a study comparing care delivered by
specialists in an HCV clinic at an academic medical center with
HCV care and treatment delivered by primary care providers
participating in teleECHO clinics, investigators found that care
at both settings was equally safe and effective in achieving cure
(6). Project ECHO also has been shown to develop knowledge
and self-efficacy among participating primary care providers
to deliver best-practice care for chronic HCV infection (7).
Each state adapted the Project ECHO model to fit expected
needs of its program. In Utah, the health department played an
important role in case finding, including those lost to follow
up, whereas in Arizona, hepatitis C coordinators were hired to
assist clinicians with case management. Arizona also had more
frequent presentations (each patient was seen every week), and
treatment initiations were synchronized by site.
The findings in this report are subject to at least four limitations. First, treatment completion among some patients who
started treatment could not be assessed because patients were
either on treatment or had completed therapy and had pending laboratory data at the time of this evaluation. Second,
the reasons that treatment was not initiated for some patients
could not be assessed. Third, the analysis did not compare
differences between Project ECHO implementation in each
state and patient treatment decisions. Finally, both Utah
and Arizona had either developed a Project ECHO–based
program or were in the process of developing it during the 1
year before September 2012; therefore, these state programs
might not be representative of programs that might be earlier
in development.
CDC and the U.S. Preventive Services Task Force recommend HCV testing for persons born during 1945–1965 and
others at risk for HCV infection (8). Studies have revealed

What is already known on this topic?
In the United States, about 3 million persons are estimated to be
living with hepatitis C virus (HCV) infection, which is an important
cause of morbidity and mortality. However, there is a documented lack of expertise in HCV-related care and treatment
among U.S. primary care providers and limited access to
specialists, both of which serve as barriers to life-saving treatment
for those who are infected. The Extension for Community
Healthcare Outcomes project (Project ECHO) has been shown to
be an effective model to overcome these barriers.
What is added by this report?
The Project ECHO model was successfully implemented in two
states, training 66 primary care clinicians, predominantly from
rural settings. Nearly all (93%) of the clinicians had no prior
experience in care and treatment of HCV infection. In both
states combined, 46% of HCV-infected patients seen in
teleECHO clinics received antiviral treatment, a proportion that
was more than twice that observed in a CDC study, further
demonstrating the utility of this approach in expanding the
capacity of primary care providers to treat HCV infection.
What are the implications for public health practice?
The Project ECHO model is an effective evidence-based model
that can be used by state and local areas to enhance capacity
to manage and treat HCV infection, especially among underserved populations.

that full implementation of these recommendations can avert
approximately 120,000 HCV-associated deaths (9). However,
limitations in care capacity, particularly in rural areas and other
resource-constrained settings, are barriers to achieving the
public health benefits of HCV testing, care, and treatment.
With training and supervision by specialists, HCV antiviral
treatment can be safely and effectively delivered in primary care
settings (6,10). Additional safe and effective HCV therapies
currently under development could provide new options for
primary care clinicians to incorporate management of HCV
infection into their practices. Collaborations with specialists
will help primary care providers to begin to incorporate new
treatments for HCV infection and will be an important measure for improving access and reducing barriers to treatment.
The results of this evaluation demonstrate Project ECHO as a
model that can enhance primary care provider capacity to treat
HCV infection among underserved populations, including the
use of newly approved medications.
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